Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see
how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating
patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide
may help the immune system kill abnormal blood cells or cancer cells. Drugs used in
chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more
or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with
multiple myeloma